Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

被引：0
|
作者：
Agius, M. [1 ]
Klodowska-Duda, G. [2 ]
Maciejowski, M. [3 ]
Potemkowski, A. [4 ]
Sweeny, S. [5 ]
Li, J. [6 ]
Yao, W. [5 ]
Patra, K. [5 ]
Ratchford, J. N. [5 ]
Katz, E. [5 ]
Flor, A. [5 ]
机构：
[1] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA
[2] Neurocare, Katowice, Poland
[3] KMK Clin Sp Zoo, NZOZ RAWA MED, Katowice, Poland
[4] Osrodek Badan Klin Znych Indywidualnej Specjalist, Szczecin, Poland
[5] Medimmune Inc, Gaithersburg, MD 20878 USA
[6] MedImmune, Mountain View, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P528
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of ofatumumab versus placebo in relapsing multiple sclerosis patients in japan and russia: results from the phase 2 apolitos study
    Kira, J. -I.
    Nakahara, J.
    Sazonov, D. V.
    Kurosawa, T.
    Tsumiyama, I.
    Willi, R.
    Zalesak, M.
    Haring, D. A.
    Ramanathan, K.
    Merschhemke, M.
    Pingili, R.
    Saida, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 219 - 219
  • [42] Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Silk, Maria
    Nantz, Eric
    NEUROLOGY, 2018, 90
  • [43] Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: results of a 6-month, randomised, double-blind, placebo-controlled, phase 2 study
    Saida, T.
    Kikuchi, S.
    Itoyama, Y.
    Hao, Q.
    Kurosawa, T.
    Nagato, K.
    Tsumiyama, I.
    Zhang-Auberson, L.
    Kira, J. -I.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S418 - S419
  • [44] Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study
    Deodhar, Atul
    Supronik, Jerzy
    Kivitz, Alan
    Valenzuela, Guillermo
    Kapur, Karen
    Rohrer, Susanne
    Dokoupilova, Eva
    Richards, Hanno B.
    Pavelka, Karel
    ARTHRITIS & RHEUMATOLOGY, 2024,
  • [45] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study
    Bar-Or, A.
    Weinstock-Guttman, B.
    Mao-Draayer, Y.
    Cruz, L. -A.
    Meng, X.
    Cox, G. M.
    Cohan, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 574 - 575
  • [46] Double-Blind, Placebo-Controlled Randomized Phase II Serial MRI, Safety and Tolerability Study of Two Doses of CDP323 in Subjects with Relapsing Forms of Multiple Sclerosis over 24 Weeks
    Polman, Chris
    Bowen, James
    Barkhof, Frederik
    Bates, David
    Wynn, Daniel
    Sanders, Evert A. C. M.
    Wolf, Christian
    Morris, Tony
    Duda, Petra
    Weinkauf, Birgit
    Lynn, Frances
    Bennett, Barbara
    NEUROLOGY, 2010, 74 (09) : A293 - A293
  • [47] Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial
    Olsson, T.
    Boster, A.
    Fernandez, O.
    Freedman, M. S.
    Pozzilli, C.
    Bach, D.
    Berkani, O.
    Mueller, M.
    Sidorenko, T.
    Melanson, M.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 49 - 50
  • [48] Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S20 - S20
  • [49] Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen
    NEUROLOGY, 2011, 76 (09) : A545 - A545
  • [50] Safety and tolerability of IMU-838, a next-generation DHODH inhibitor in EMPhASIS: a randomized, placebo-controlled phase 2 trial in relapsing multiple sclerosis
    Fox, R. J.
    Wiendl, H.
    de Stefano, N.
    Sellner, J.
    Muehler, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 557 - 557
12345